Logo

American Heart Association

  2
  0


Final ID: Sa3064

Bidirectional Associations of Chronic Kidney Disease and Heart Failure are Frequent and Associated with Higher Mortality: The Atherosclerosis Risk in Communities (ARIC) Study

Abstract Body (Do not enter title and authors here): Background: Chronic kidney disease (CKD) and heart failure (HF) are interrelated but the bidirectional associations between the two conditions are not completely understood.

Hypothesis: Bidirectional associations between CKD and HF are common in ambulatory populations and have implications for survival.

Methods: We conducted a prospective cohort study of 11595 participants who attended ARIC Visit 4 (1996-98) with data on prevalent CKD and HF status, with follow-up for incident events through 2021. We assessed the prospective association of prevalent CKD (defined as eGFR<60 ml/min per 1.73 m2 or urine albumin-creatinine ratio of ≥30 mg/g) at Visit 4 with incident HF. We also assessed the association of prevalent HF at Visit 4 with incident CKD through 2019. Analyses accounted for mortality as a competing risk. We cross-categorized CKD and HF at Visit 4 and assessed prospective associations with mortality relative to those with neither condition.

Results: The mean age in the study population was 63 years, with 56% women; and 23% Black adults. Among 1222 with prevalent CKD, 529 (43%) developed HF; among 433 with prevalent HF, 137 (31%) developed CKD. After multivariable adjustment, prevalent CKD (vs no CKD) was associated with incident HF (HR 1.87; 95% CI, 1.65–2.12; Figure). Prevalent HF (vs no HF) was also associated with incident CKD (HR 1.33; 95% CI, 1.09–1.62). The co-occurrence of prevalent CKD and HF was associated with greater mortality risk (HR, 2.07; 95% CI, 1.78–2.42) than prevalent CKD alone (HR, 1.47; 95% CI, 1.37–1.59) or prevalent HF alone (HR, 1.33; 95% CI, 1.18–1.50), when compared with neither condition (pinteraction<0.001).

Conclusions: Bidirectional associations between CKD and HF are common in ambulatory populations. The co-existence of both CKD and HF is associated with higher mortality compared to either alone. There is a need to refine strategies to mitigate risk associated with bidirectional CKD and HF associations.
  • Luo, Shengyuan  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Selvin, Elizabeth  ( JOHNS HOPKINS UNIVERSITY , Baltimore , Maryland , United States )
  • Coresh, Joe  ( New York University , New York , New York , United States )
  • Ndumele, Chiadi  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Zhang, Sui  ( Johns Hopkinds University , Baltimore , Maryland , United States )
  • Echouffo, Justin  ( Johns Hopkins Hospital , Baltimore , Maryland , United States )
  • Nambi, Vijay  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
  • Shah, Amil  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Minhas, Anum  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Matsushita, Kuni  ( JOHNS HOPKINS UNIVERSITY , Baltimore , Maryland , United States )
  • Grams, Morgan  ( New York University , New York , New York , United States )
  • Author Disclosures:
    Shengyuan Luo: DO NOT have relevant financial relationships | Elizabeth Selvin: DO NOT have relevant financial relationships | Joe Coresh: No Answer | Chiadi Ndumele: DO NOT have relevant financial relationships | Sui Zhang: DO NOT have relevant financial relationships | Justin Echouffo: DO NOT have relevant financial relationships | VIJAY NAMBI: DO have relevant financial relationships ; Researcher:Abbott Labs:Past (completed) ; Individual Stocks/Stock Options:Insera:Active (exists now) ; Researcher:Ionis:Active (exists now) | Christie Ballantyne: DO have relevant financial relationships ; Independent Contractor:Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk:Active (exists now) ; Consultant:Abbott Diagnostic, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Eli Lilly, Esperion, Illumina, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic, TenSixteen Bio:Active (exists now) | Amil Shah: DO have relevant financial relationships ; Advisor:Philips Ultrasound:Past (completed) ; Advisor:Janssen:Past (completed) | Anum Minhas: DO NOT have relevant financial relationships | Kuni Matsushita: DO have relevant financial relationships ; Consultant:RhythmX AI:Active (exists now) ; Research Funding (PI or named investigator):Resolve to Save Lives:Active (exists now) ; Other (please indicate in the box next to the company name):Fukuda Denshi:Past (completed) | Morgan Grams: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

CVD Science Smorgasbord I

Saturday, 11/16/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
A Scoping Review Exploring Cardiovascular Risk and Health Metrics and Cancer Prediction

Kim Ji-eun, Henriquez Santos Gretell, Kumar Sant, Livinski Alicia, Vo Jacqueline, Joo Jungnam, Shearer Joe, Hashemian Maryam, Roger Veronique

5-oxoproline/ OPLAH Axis Alleviates Doxorubicin-induced Cardiomyopathy By Inhibiting Ferroptosis

Jiang Meng, Guo Xinning

More abstracts from these authors:
The Association of PREVENT-HF Risk Estimates with Subclinical (Stage B) HF and Clinical Implications for HF Risk: The Atherosclerosis Risk in Communities (ARIC) Study

Grant Jelani, Matsushita Kuni, Shah Amil, Coresh Joe, Ndumele Chiadi, Zhang Sui, Khan Sadiya, Ozkan Bige, Nambi Vijay, Pandey Ambarish, Blumenthal Roger, Ballantyne Christie, Selvin Elizabeth

Transitions Across Stages of Cardiovascular-Kidney-Metabolic Syndrome and Related Implications for Cardiovascular Disease Risk: the ARIC Study

Ozkan Bige, Ndumele Chiadi, Zhang Sui, Nambi Vijay, Rangaswami Janani, Echouffo Justin, Blumenthal Roger, Ballantyne Christie, Khan Sadiya, Coresh Josef

You have to be authorized to contact abstract author. Please, Login
Not Available